MATTHEW SCHULKE: Open Payments
NPI 1861908576 · KYLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,944 in 121 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $481 · 2025 $1,944
Food & beverage: $1,857Education: $87
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 47 | $668 |
| Alkermes, Inc. | 21 | $281 |
| Neurocrine BioSciences, Inc. | 17 | $271 |
| Otsuka America Pharmaceutical, Inc. | 12 | $209 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $171 |
| E.R. Squibb & Sons, L.L.C. | 6 | $170 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| ABBVIE INC. | 1 | $17 |
Products named: UZEDY, INGREZZA, ARISTADA, CAPLYTA, COBENFY, REXULTI, ABILIFY ASIMTUFII, Auvelity.
Industry payments across TX — which companies pay providers there.
